Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dutasteride/tadalafil - Dongkook Pharmaceutical

Next Previous
Drug Profile

Dutasteride/tadalafil - Dongkook Pharmaceutical

Alternative Names: DKF 313; Tadalafil/dutasteride - Dongkook Pharmaceutical

Latest Information Update: 15 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dongkook Pharmaceutical
  • Class Antiandrogens; Antihypertensives; Antineoplastics; Aza compounds; Azasteroids; Benzodioxoles; Carbolines; Erectile dysfunction therapies; Eye disorder therapies; Fluorinated hydrocarbons; Gastrokinetics; Heart failure therapies; Indenes; Indoles; Ischaemic heart disorder therapies; Ketones; Pyridones; Quinolines; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Cholestenone 5 alpha-reductase inhibitors; Testosterone antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Benign prostatic hyperplasia

Most Recent Events

  • 31 Mar 2025 Registered for Benign prostatic hyperplasia in South Korea (PO), before March 2025
  • 31 Dec 2024 Preregistration for Benign prostatic hyperplasia in South Korea (PO), before December 2024
  • 31 Dec 2024 Dongkook Pharmaceuticals plans to launch dutasteride/tadafil for Benign prostatic hyperplasia in South Korea (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top